Exblifep was designed to combat antimicrobial resistance in gram-negative bacteria, especially resistance mediated by Extended Spectrum Beta Lactamases (or ESBLs). Approval was based on the Phase 3 ALLIUM trial which met criteria for non-inferiority and superiority compared to piperacillin/tazobactam ...
covering common Gram-positive and Gram-negative bacteria, and is sensitive even to Enterobacteriaceae and anaerobic bacteria that produce ESBLs enzymes. It is especially suitable for the treatment of community-acquired pneumonia in the elderly.
Extended-spectrum 尾-lactamase (ESBL)-producing pathogenic E. coli is a global public health issue, especially in sub-Saharan African countries such as Ca... S Mahamat,RC Founou,LL Founou,... - 《Bmc Microbiology》 被引量: 0发表: 2024年 Treating diarrhoea: what might the pituitary offer...
Non-susceptibility trends among Enterobacteriaceae from bacteraemias in the UK and Ireland, 2001-06. J Antimicrob Chemother. 2008;62(Suppl 2):ii41–54. CAS PubMed Google Scholar Knudsen JD, Andersen SE, Grp BI. A multidisciplinary intervention to reduce infections of ESBL-and AmpC-producing,...
9 RegisterLog in Sign up with one click: Facebook Twitter Google Share on Facebook MBL Medical Wikipedia Category filter: AcronymDefinition MBLMacquarie Bank Limited MBLMobile MBLMarine Biological Laboratory MBLMedical & Biological Laboratories(Japan) ...